NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Copyright Public domain Remove constraint Copyright: Public domain Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

8. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

11. ACF cannot ensure that all child victims of abuse and neglect have court representation

12. ACOs' strategies for transitioning to value-based care: lessons from the Medicare shared savings program

16. Accelerating adoption of assistive technology to reduce physical strain among family caregivers of the chronically disabled elderly living at home

18. Access and use of electronic health information by individuals with cancer: 2017-2018

20. The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

21. Acne vulgaris: establishing effectiveness of drugs intended for treatment

23. Adaptive designs for clinical trials of drugs and biologics

27. Addressing teen pregnancy risks for youth living in out-of-home care: implementing POWER through choices 2010 : implementation report

28. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

29. The Admissibility of Scientific Evidence in Court

30. Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees

31. Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report

33. Advancement of emerging technology applications for pharmaceutical innovation and modernization

35. Adverse events in long-term-care hospitals: national incidence among Medicare beneficiaries

36. The Affordable Care Act and African Americans

37. The Affordable Care Act and Asian Americans and Pacific Islanders

38. The Affordable Care Act and Latinos

39. The Affordable Care Act and adolescents

40. The Affordable Care Act and women

41. Affordable Care Act has led to historic, widespread increase in health insurance coverage

42. Affordable Care Act: IRS should mitigate limitations of data to be used for the age and gender adjustment for the tax on high-cost health plans : report to Congressional committees

43. The Affordable Care Act: advancing the health of women and children

45. The aging services network: accomplishments and challenges in serving a growing elderly population

46. Air ambulance: data collection and transparency needed to enhance DOT oversight : report to the Committee on Transportation and Infrastructure, House of Representatives

48. Air travel and communicable diseases: status of research efforts and action still needed to develop federal preparedness plan : testimony before the Subcommittee on Space and Aeronautics, Committee on Science, Space, and Technology, House of Representatives

51. [Albino children]

52. Allergic rhinitis: developing drug products for treatment

53. Alopecia areata Celsi

57. An American Indian/Alaska Native suicide prevention hotline: literature review and discussion with experts

58. [Amphioxus and ascidian]

59. Amyotrophic lateral sclerosis: developing drugs for treatment

60. Analysis of 2017 premium changes and insurer participation in the Affordable Care Act's health insurance marketplaces

61. An analysis of private-sector prices for hospital admissions

63. Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV): final report

65. [Anatomy of vision]

69. Anthrax: developing drugs for prophylaxis of inhalational anthrax

70. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

72. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

73. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

76. Appeal options available to mammography facilities concerning adverse accreditation decisions, suspension/revocation of certificates, or patient and physician notification orders: guidance for mammography facilities and Food and Drug Administration staff

80. Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff

88. Arthroscopy pump tubing sets intended for multiple patient use - Premarket Notification (510(k)) submissions: guidance for industry and Food and Drug Administration staff

89. Artificial intelligence in health care: benefits and challenges of machine learning technologies for medical diagnostics : report to congressional requesters

90. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

91. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment

95. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

96. Assessing user fees under the biosimilar user fee amendments of 2017

99. Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries